Hansen Medical, Inc. (NASDAQ:HNSN), a global leader in intravascular robotics, today announced that its Board of Directors has appointed industry veteran Cary Vance as the Company’s President and Chief Executive Officer, and a member of the Board of Directors, effective as of May 23, 2014. Hansen Medical, Inc. (NASDAQ:HNSN) weekly performance is -35.12%. On last trading day company shares ended up $1.33. Analysts mean target price for the company is $2.00. Hansen Medical, Inc. (NASDAQ:HNSN) distance from 50-day simple moving average (SMA50) is -42.96%.
LDR Holding Corporation (Nasdaq:LDRH), a global medical device company focused on designing and commercializing novel and exclusive device technologies for the treatment of patients suffering from spine disorders, announced today that six presentations were delivered on the Mobi-C Cervical Disc (Mobi-C) at the 2014 International Society for the Advancement of Spine Surgery (ISASS) meeting. The presentations highlighted the results of the Mobi-C one and two-level Investigational Device Exemption (IDE) clinical trial. The presentations provided patient outcomes up to 48-month follow-up, and represent the most Mobi-C results presented at any one given venue to date. Holding Corp (NASDAQ:LDRH) shares fell -5.44% in last trading session and ended the day on $23.65. LDRH Gross Margin is 84.00% and its return on assets is -30.80%. LDR Holding Corp (NASDAQ:LDRH) quarterly performance is -5.21%.
BioLife Solutions, Inc. (NASDAQ:BLFS) a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues (“BioLife” or the “Company”), today announced financial results for the first quarter of 2014 and a business update. BioLife Solutions Inc (NASDAQ:BLFS) shares moved down -3.38% in last trading session and was closed at $2.00, while trading in range of $1.91 – $2.39 -. BioLife Solutions Inc (NASDAQ:BLFS) year to date (YTD) performance is -76.19%.
Boston Scientific Corporation (NYSE:BSX) has signed a definitive agreement to acquire IoGyn, Inc., a pre-commercial stage company. The transaction is expected to close within days. IoGyn has developed and received U.S. Food and Drug Administration (FDA) clearance for the Symphion™ System, a next generation system for hysteroscopic intrauterine tissue removal including fibroids (myomas) and polyps. This acquisition enables the pairing of the Symphion System with the Boston Scientific Genesys HTA™ System for abnormal uterine bleeding, to create a compelling set of gynecologic surgery products. Boston Scientific Corporation (NYSE:BSX) ended the last trading day at $12.80. Company weekly volatility is calculated as 2.49 % and price to cash ratio as 2.37. Boston Scientific Corporation (NYSE:BSX) showed a positive weekly performance of 1.59%.a